Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 476Carcinoma, Non-Small-Cell Lung 233Breast Neoplasms 196Ovarian Neoplasms 171Glioblastoma 157Carcinoma, Hepatocellular 131Neoplasms 128Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 106Brain Neoplasms 98Lung Neoplasms 96Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 77Glioma 69Pancreatic Neoplasms 54Liver Neoplasms 44Melanoma 43Gliosarcoma 43Uterine Cervical Neoplasms 40Adenocarcinoma of Lung 39Stomach Neoplasms 37Recurrence 33Astrocytoma 30Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Triple Negative Breast Neoplasms 26Kidney Neoplasms 23Prostatic Neoplasms 22Esophageal Neoplasms 21

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Melphalan 9Interleukin-2 9CTLA-4 Antigen 8tebentafusp 7sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Blood Specimen Collection 5Bevacizumab 5aldesleukin 4aflibercept 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4trametinib 3sotrastaurin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Uveal Melanoma × Bevacizumab × Clear all
NCT05075993 2025-12-26

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
352 enrolled
DermatologicGastrointestinalGynecologicSarcoma

Uveal Melanoma, Carcinoma, Hepatocellular, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Academic and Community Cancer Research United

Phase 2 Completed
24 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT01471054 2019-09-03

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Wills Eye

Phase 2 Terminated
6 enrolled 10 charts
Dermatologic

Uveal Melanoma, Macular Edema

NCT00596362 2016-06-17

Treatment With Intravitreal Avastin for Large Uveal Melanomas

Memorial Sloan Kettering Cancer Center

Phase NA Completed
1 enrolled 3 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT01217398 2013-08-26

Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Unknown
35 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡